These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 32169057)

  • 21. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine.
    Bouzeman A; Traulle S; Messali A; Extramiana F; Denjoy I; Narayanan K; Marijon E; Hermida JS; Leenhardt A
    Europace; 2014 Apr; 16(4):572-7. PubMed ID: 24068450
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Makarawate P; Chaosuwannakit N; Vannaprasaht S; Sahasthas D; Koo SH; Lee EJD; Tassaneeyakul W; Barajas-Martinez H; Hu D; Sawanyawisuth K
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28584071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous cardioverter defibrillator has longer time to therapy but is less cardiotoxic than transvenous cardioverter defibrillator. Study carried out in a preclinical porcine model.
    Garcia R; Inal S; Favreau F; Jayle C; Hauet T; Bruneval P; Kerforne T; Hajj-Chahine J; Degand B
    Europace; 2018 May; 20(5):873-879. PubMed ID: 28460030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study.
    Sacher F; Probst V; Iesaka Y; Jacon P; Laborderie J; Mizon-Gérard F; Mabo P; Reuter S; Lamaison D; Takahashi Y; O'Neill MD; Garrigue S; Pierre B; Jaïs P; Pasquié JL; Hocini M; Salvador-Mazenq M; Nogami A; Amiel A; Defaye P; Bordachar P; Boveda S; Maury P; Klug D; Babuty D; Haïssaguerre M; Mansourati J; Clémenty J; Le Marec H
    Circulation; 2006 Nov; 114(22):2317-24. PubMed ID: 17116772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is ICD-programming for double intraoperative defibrillation threshold energy safe and effective during long-time follow-up? Results of a prospective randomized multicenter study (Low-Energy Endotak Trial--LEET)].
    Himmrich E; Liebrich A; Michel U; Neuzner J; Pitschner H; Heisel A; Vester E; Ganschov U; Jung J
    Z Kardiol; 1999 Feb; 88(2):103-12. PubMed ID: 10209831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Efficacy and Necessity of Routine Defibrillation Threshold Testing in Patients Undergoing Implantable Cardioverter-Defibrillator (ICD) Implantation.
    Ashino S; Nakai T; Sonoda K; Sasaki N; Kurokawa S; Ikeya Y; Okumura Y; Ohkubo K; Kunimoto S; Watanabe I; Hirayama A
    Int Heart J; 2015; 56(6):618-21. PubMed ID: 26549282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful implantation of cardiac defibrillators without induction of ventricular fibrillation using upper limit of vulnerability testing.
    Green UB; Garg A; Al-Kandari F; Ungab G; Tone L; Feld GK
    J Interv Card Electrophysiol; 2003 Feb; 8(1):71-5. PubMed ID: 12652181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Implantable cardioverter-defibrillator oversensing due to electric shock].
    Jurcević R; Angelkov L; Vukajlović D; Ristić V; Tomović M; Djukanović B
    Srp Arh Celok Lek; 2010; 138(3-4):236-9. PubMed ID: 20499508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defibrillation failure in patients undergoing replacement of subcutaneous defibrillator pulse generator.
    Rudic B; Tülümen E; Fastenrath F; Akin I; Borggrefe M; Kuschyk J
    Heart Rhythm; 2020 Mar; 17(3):455-459. PubMed ID: 31669771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circadian and seasonal variations of ventricular tachyarrhythmias in patients with early repolarization syndrome and Brugada syndrome: analysis of patients with implantable cardioverter defibrillator.
    Kim SH; Nam GB; Baek S; Choi HO; Kim KH; Choi KJ; Joung B; Pak HN; Lee MH; Kim SS; Park SJ; On YK; Kim JS; Oh IY; Choi EK; Oh S; Choi YS; Choi JI; Park SW; Kim YH; Lee MY; Lim HE; Lee YS; Cho Y; Kim J; Lee DI; Cho DK; Kim YH
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):757-63. PubMed ID: 22353358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Potential Impact of Intrathoracic Impedance on Defibrillation Threshold Testing in S-ICDs.
    Cheung CC; Larsen JM; Bashir J; Dorian P; Laksman ZW
    Can J Cardiol; 2019 Nov; 35(11):1604.e13-1604.e16. PubMed ID: 31587933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy.
    Kitamura T; Fukamizu S; Kawamura I; Hojo R; Aoyama Y; Komiyama K; Nishizaki M; Hiraoka M; Sakurada H
    Heart Rhythm; 2016 Jul; 13(7):1455-9. PubMed ID: 26961302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome.
    Takigawa M; Noda T; Shimizu W; Miyamoto K; Okamura H; Satomi K; Suyama K; Aihara N; Kamakura S; Kurita T
    Heart Rhythm; 2008 Nov; 5(11):1523-7. PubMed ID: 18984526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous chronic implantable defibrillation systems in humans.
    Cappato R; Smith WM; Hood MA; Crozier IG; Jordaens L; Spitzer SG; Ardashev AV; Boersma L; Lupo P; Grace AA; Bardy GH
    J Interv Card Electrophysiol; 2012 Sep; 34(3):325-32. PubMed ID: 22426601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment with an implantable cardioverter defibrillator for spontaneous ventricular fibrillation in dilated cardiomyopathy with very high defibrillation thresholds.
    Tamura K; Abe H; Nagatomo T; Nakashima Y
    J UOEH; 2001 Dec; 23(4):363-8. PubMed ID: 11789138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.